Platelet P2 receptors: old and new targets for antithrombotic drugs

References

• Abbracchio MP, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C. Characterization of the UDP-glucose receptor (re-named the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol. Sci.24, 52–55 (2003)
   PubMed Web of Science ®Google Scholar
• Boeynaems J-M, Communi D, Suarez Gonzales N, Robaye B. Overview of the P2 receptors. Sem. Thromb. Hemost.31, 139–149 (2005).
   PubMed Web of Science ®Google Scholar
• Cattaneo M. The platelet P2 receptors. In: Platelets. Michelson AD (Ed.), Academic Press, San Diego, CA, USA, 2006. In press.
   Google Scholar
• Gachet C. Regulation of platelet functions by P2 receptors. Ann. Rev. Pharmacol. Toxicol.46, 277–300 (2006)
   PubMed Web of Science ®Google Scholar
• Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb. Haemost.85(2), 303–308 (2001).
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Marchese P, Jacobson KA, Ruggeri Z. New insights into the role of P2X1 in platelet function (abstract). Haematologica87, 13–14 (2002).
   Google Scholar
• Cattaneo M, Marchese P, Jacobson KA, Ruggeri ZM. The P2X1 receptor for ATP plays an essential role in platelet aggregation at high shear. Haematology J.4(Suppl. 2), 150 (2003).
   Google Scholar
• Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb. Haemost.86(5), 1264–1271 (2001).
   PubMed Web of Science ®Google Scholar
• Oury C, Sticker E, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation. J. Biol. Chem.279(25), 26266–26273 (2004).
   PubMedGoogle Scholar
• Cattaneo M. ADP receptors antagonists. In: Platelets. Michelson AD (Ed.), Academic Press, San Diego, CA, USA 2006. In press.
   Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med.354 (online ahead publication, March 12, 2006).
   Google Scholar
• Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet1(8649), 1215–1220 (1989).
   PubMed Web of Science ®Google Scholar
• Hass WK, Easton JD, Adams HP Jr et al. randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med.321(8), 501–507 (1989).
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Richardson D, Kelly M et al. African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA289(22), 2947–2957 (2003).
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet364, 331–337 (2004).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst. Rev.2, CD001246 (2000).
   PubMedGoogle Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352(12), 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366, 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med.334(17), 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation98(16), 1597–1603 (1998).
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation98(20), 2126–2132 (1998).
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med.339(23), 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet.358, 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA294(10), 1224–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronaryintervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation.111(16), 2099–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med.350(3), 232–238 (2004).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Neumann FJ et al; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA295(13), 1531–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Bertrand ME, Berger PB et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol.39(1), 9–14 (2002).
   PubMed Web of Science ®Google Scholar
• Mueller C, Roskamm H, Neumann FJ et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J. Am. Coll. Cardiol.41(6), 969–973 (2003).
   PubMed Web of Science ®Google Scholar
• Wolak A, Amit G, Cafri C, Gilutz H, Ilia R, Zahger D. Increased long-term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. Int. J. Cardiol.103(3), 293–297 (2005).
   Google Scholar
• Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J. Intern. Med.227(5), 301–308 (1990).
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group on behalf of the ACTIVE Investigators; Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet367, 1903–1912 (2006).
   PubMed Web of Science ®Google Scholar
• Gaspoz JM, Coxson PG, Goldman PA et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N. Engl. J. Med.346(23), 1800–1806 (2002).
   PubMed Web of Science ®Google Scholar
• Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics.22 Suppl. 4, 19–27 (2004).
   PubMedGoogle Scholar
• Karnon J, Brennan A, Pandor A et al. Modelling the long-term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr. Med. Res. Opin.21(1), 101–112 (2005).
   PubMed Web of Science ®Google Scholar
• Beinart SC, Kolm P, Veledar E et al. Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. J. Am. Coll. Cardiol.46(5), 761–769 (2005).
   PubMed Web of Science ®Google Scholar
• Cowper PA, Udayakumar K, Sketch MH Jr, Peterson ED. Economic effects of prolonged clopidogrel therapy after percutaneous coronary Intervention. J. Am. Coll. Cardiol.45(3), 369–376 (2005).
   PubMed Web of Science ®Google Scholar
• Karnon J, Bakhai A, Brennan A, Flather M, Warren E, Gray D, Akehurst R. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int. J. Cardiol. 2005 Jul 15; [Epub ahead of print]
   Google Scholar
• Lamy A, Jonsson B, Weintraub WS et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur. J. Cardiovasc. Prev. Rehabil.11(6), 460–465 (2004).
   PubMed Web of Science ®Google Scholar
• Lindgren P, Jonsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J. Intern. Med.255(5), 562–570 (2004).
   PubMed Web of Science ®Google Scholar
• Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann. Intern. Med.142(4), 251–259 (2005).
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Mahoney EM, Lamy A et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J. Am. Coll. Cardiol.45(6), 838–845 (2005).
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol.24, 1980–1987(2004).
   PubMed Web of Science ®Google Scholar
• TaubertD, Kastrati A, Harlfinger S et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost.92(2), 311–316 (2004).
   PubMed Web of Science ®Google Scholar
• von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis.16(3), 199–204 (2005).
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (Prasugrel, LY-640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Sem. Thromb. Hemost.31, 184–194 (2005).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Winters KJ et al. Randomized comparison of prasugrel (CS-747, LY-640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation.111(25), 3366–3373 (2005).
   PubMed Web of Science ®Google Scholar
• van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Sem. Thromb. Hemost.31, 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost.85, 401–407 (2001).
   PubMed Web of Science ®Google Scholar
• Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets.13(7), 407–413 (2002).
   PubMed Web of Science ®Google Scholar
• Beham M, Fox S, Sanderson H, Storey R, Heptinstall S. Effect of Clopidogrel on procoagulant activity in acute coronary syndromes: Evidence for incomplete P2Y12 receptor blockade. Circulation.106, II 149-II 150 (2002).
   Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmakodynamic, pharmacokinetic and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. (2006) (In Press).
   Google Scholar
• Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S et al. Anti-aggregatory activity in human platelets of potent antagonists of the P2Y(1) receptor. Biochem. Pharmacol.68(10), 1995–2002 (2004).
   PubMed Web of Science ®Google Scholar
• Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F et al. MRS2500, a potent, selective and stable antagonist of the P2Y1 receptor, with strong antithrombotic activity in mice. J. Pharmacol. Exp. Ther.316(2), 556–563 (2006).
   PubMedGoogle Scholar
• Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X(1) receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br. J. Pharmacol.131(1), 108–114 (2000).
   PubMedGoogle Scholar
• Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation. J. Biol. Chem.278(47), 46661–46667 (2003).
   PubMedGoogle Scholar
• Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood.100(7), 2499–2505 (2002).
   PubMed Web of Science ®Google Scholar
• Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M et al. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J. Exp. Med.198(4), 661–667 (2003).
   PubMed Web of Science ®Google Scholar
• Erhardt JA, Pillarisetti K, Toomey JR. Potentiation of platelet activation through the stimulation of P2X1 receptors. J. Thromb. Haemost.1(12), 2626–2635 (2003).
   PubMedGoogle Scholar
• Kawa K. Thrombopoietin enhances rapid current responses mediated by P2X1 receptors on megakaryocytic cells in culture. Jpn. J. Physio.l53, 287–299 (2003).
   PubMedGoogle Scholar
• Fung CY, Brearley CA, Farndale RW, Mahaut-Smith MP. A major role for P2X1 receptors in the early collagen-evoked intracellular Ca2+ responses of human platelets. Thromb. Haemost.94(1), 37–40 (2005).
   PubMedGoogle Scholar
• Mulryan K, Gitterman DP, Lewis CJ et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature403, 86–89 (2000).
   PubMed Web of Science ®Google Scholar
• Hechler B, Magnenat S, Zighetti ML et al. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4’,4’’,4’’’-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonicacidoctasodiumsalt]. J. Pharmacol. Exp. Ther.314(1), 232–43 (2005).
   PubMed Web of Science ®Google Scholar
• Horner S, Menke K, Hildebrandt C et al. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the nanomolar range. Naunyn-Schmiedebergs Arch. Pharmacol.372, 1–13 (2005).
   PubMedGoogle Scholar